# Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil

> **NCT03330899** · PHASE1 · COMPLETED · sponsor: **Butantan Institute** · enrollment: 432 (actual)

## Conditions studied

- Influenza
- H7N9 Influenza

## Interventions

- **BIOLOGICAL:** H7N9 antigen + adjuvant IB160
- **BIOLOGICAL:** H7N9 antigen + adjuvant SE
- **BIOLOGICAL:** H7N9 antigen without adjuvant
- **BIOLOGICAL:** Placebo (PBS)

## Key facts

- **NCT ID:** NCT03330899
- **Lead sponsor:** Butantan Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-24
- **Primary completion:** 2020-01-30
- **Final completion:** 2020-08-25
- **Target enrollment:** 432 (ACTUAL)
- **Last updated:** 2020-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03330899

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03330899, "Safety and Immunogencity of H7N9 Influenza Antigen With 2 Adjuvant Formulations in Healthy Adults in Brazil". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03330899. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*